KRAS and colorectal carcinoma: Nakadate and colleague reported that CRC cells harboring a KRAS-G13 mutation display resistance to cetuximab (anti-EGFR IgG1)-mediated antibody-dependent cellular cytotoxicity (ADCC) which involves Fas-FasL interaction (6).